Evidence map›Paper›PMID 24563463›Full record

ArticleThe Journal of biological chemistry2014

Menin is required for optimal processing of the microRNA let-7a.

Buddha Gurung, Abdul Bari Muhammad, Xianxin Hua

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Epigenetic regulation by the menin pathway.Endocrine-related cancer · 2017
    Review
  4. Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB.American journal of physiology. Endocrinology and metabolism · 2017
    Article
  5. Article
  6. Polymorphisms of microRNA target genesWorld journal of gastroenterology · 2017
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Buddha GurungFrom the Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104.
Abdul Bari Muhammad
Xianxin Hua
University of Pennsylvania · US

Funding

Beta Cell Regeneration by an Epigenetic PathwayR01DK097555 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HUA, XIANXIN · 2013 to 2016
$1.4M
Regulation of apoptosis by meninR01CA113962 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HUA, XIANXIN · 2005 to 2009
$1.4M
Link of Beta Cell Proliferation and Type 2 Diabetes to Epigenetic RegulationR01DK085121 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HUA, XIANXIN · 2010 to 2013
$1.4M
NCI NIH HHS R01 CA113962NCI NIH HHS R01-CA-113962NIDDK NIH HHS R01 DK085121NIDDK NIH HHS R01-DK085121NIDDK NIH HHS R01 DK097555
6 · The paper itself

Abstract

Multiple endocrine neoplasia type I (MEN1) is an inherited syndrome that includes susceptibility to pancreatic islet hyperplasia. This syndrome results from mutations in the MEN1 gene, which encodes menin protein. Menin interacts with several transcription factors, including JunD, and inhibits their activities. However, the precise mechanism by which menin suppresses gene expression is not well understood. Here, we show that menin interacts with arsenite-resistant protein 2 (ARS2), a component of the nuclear RNA CAP-binding complex that is crucial for biogenesis of certain miRNAs including let-7a. The levels of primary-let-7a (pri-let-7a) are not affected by menin; however, the levels of mature let-7a are substantially decreased upon Men1 excision. Let-7a targets, including Insr and Irs2, pro-proliferative genes that are crucial for insulin-mediated signaling, are up-regulated in Men1-excised cells. Inhibition of let-7a using anti-miRNA in wild type cells is sufficient to enhance the expression of insulin receptor substrate 2 (IRS2) to levels observed in Men1-excised cells. Depletion of menin does not affect the expression of Drosha and CBP80, but substantially impairs the processing of pri-miRNA to pre-miRNA. Ars2 knockdown decreased let-7a processing in menin-expressing cells but had little impact on let-7a levels in menin-excised cells. As IRS2 is known to mediate insulin signaling and insulin/mitogen-induced cell proliferation, these findings collectively unravel a novel mechanism whereby menin suppresses cell proliferation, at least partly by promoting the processing of certain miRNAs, including let-7a, leading to suppression of Irs2 expression and insulin signaling.

Indexed as

Gene Expression Regulation, NeoplasticRNA Processing, Post-TranscriptionalAnimalsAntigens, CDCell ProliferationDNA-Binding ProteinsGene Knockdown TechniquesHEK293 CellsHumansInsulin Receptor Substrate ProteinsMiceMicroRNAsMultiple Endocrine Neoplasia Type 1Neoplasm ProteinsNuclear Cap-Binding Protein ComplexNuclear ProteinsAntigens, CDDNA-Binding ProteinsDROSHA protein, humanDrosha protein, mouseINSR protein, humanInsulin Receptor Substrate ProteinsIRS2 protein, humanIrs2 protein, mouseMEN1 protein, humanMen1 protein, mouseMicroRNAsmirnlet7 microRNA, humanmirnlet7 microRNA, mouseNeoplasm ProteinsNuclear Cap-Binding Protein ComplexNuclear ProteinsProto-Oncogene ProteinsReceptor, InsulinRibonuclease IIIRNA, NeoplasmSRRT protein, humanSrrt protein, mouseTranscription FactorsBeta CellCancer BiologyIRS2let-7aMeninMicroRNAPancreasPancreatic IsletsTumor Suppressor Gene

Identifiers

PMID24563463
PMCPMC3975034
OpenAlexW2006968758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.